Invesco
CATX icon

Invesco’s Perspective Therapeutics CATX Stock Holding History

Invesco’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$965K Buy
231,355
+207,077
+853% +$875K ﹤0.01% 2881
2025
Q4 		$66.8K Sell
24,278
-434
-2% -$1.24K ﹤0.01% 3676
2025
Q3 		$84.8K Buy
24,712
+2,503
+11% +$9.13K ﹤0.01% 3702
2025
Q2 		$76.4K Sell
22,209
-533
-2% -$1.41K ﹤0.01% 3682
2025
Q1 		$48.4K Sell
22,742
-2,432
-10% -$7.3K ﹤0.01% 3700
2024
Q4 		$80.3K Buy
25,174
+587
+2% +$4.79K ﹤0.01% 3649
2024
Q3 		$328K Buy
24,587
+1,064
+5% +$14.2K ﹤0.01% 3388
2024
Q2 		$235K Buy
+23,523
New +$340K ﹤0.01% 3573
2019
Q1 		– Sell
-1,632
Closed -$5K – 3716
2018
Q4 		$5K Sell
1,632
-93
-5% -$398 ﹤0.01% 3792
2018
Q3 		$9K Buy
1,725
+100
+6% +$557 ﹤0.01% 3866
2018
Q2 		$7K Buy
+1,625
New +$7.52K ﹤0.01% 3860
2014
Q4 		– Sell
-2,908
Closed -$49K – 4073
2014
Q3 		$49K Buy
+2,908
New +$72K ﹤0.01% 3962

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco's CATX Position: Q1 2026 in Review

Invesco increased its Perspective Therapeutics (CATX) stake by 853% in Q1 2026, buying an estimated $875K and bringing the position to 231,355 shares worth $965K. The position accounts for ﹤0.01% of the portfolio, ranked #2881.

Invesco first reported a position in CATX in Q3 2014 and has held it in 12 quarters since. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Invesco held 231,355 shares of Perspective Therapeutics worth $965K as of Q1 2026.
  • Invesco bought 207,077 Perspective Therapeutics shares in Q1 2026, an estimated $875K.
  • Perspective Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2881 holding.
  • Invesco first reported a position in Perspective Therapeutics in Q3 2014 and has held it in 12 quarters since.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.